vTv Therapeutics Inc
VTVT29.020USD
-1.990-6.42%
終値 02/06, 16:00（ET）15分遅れの株価
114.28M時価総額
損失額直近12ヶ月PER
詳細情報 vTv Therapeutics Inc 企業名
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
vTv Therapeutics Incの企業情報
企業コードVTVT
会社名vTv Therapeutics Inc
上場日Jul 30, 2015
最高経営責任者「CEO」Sekhri (Paul Jai)
従業員数23
証券種類Ordinary Share
決算期末Jul 30
本社所在地3980 Premier Dr
都市HIGH POINT
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号27265
電話番号13368410300
ウェブサイトhttps://vtvtherapeutics.com/
企業コードVTVT
上場日Jul 30, 2015
最高経営責任者「CEO」Sekhri (Paul Jai)
vTv Therapeutics Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Paul Jai Sekhri
Mr. Paul Jai Sekhri
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
5.00K
-24062.00%
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Independent Director
Independent Director
2.15K
+2146.00%
Dr. Raymond Cheong, M.D., Ph.D.
Dr. Raymond Cheong, M.D., Ph.D.
Independent Director
Independent Director
1.83K
+1833.00%
Mr. Richard S. (Rich) Nelson
Mr. Richard S. (Rich) Nelson
Executive Vice President - Corporate Development, Director
Executive Vice President - Corporate Development, Director
--
--
Mr. Fahed Al Marzooqi, M.D.
Mr. Fahed Al Marzooqi, M.D.
Independent Director
Independent Director
--
--
Mr. Burns Mcclellan
Mr. Burns Mcclellan
Investor Relations
Investor Relations
--
--
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
-2251.00%
Mr. Daniel (Dan) Spiegelman
Mr. Daniel (Dan) Spiegelman
Director
Director
--
--
Dr. Michael Tung, M.D.
Dr. Michael Tung, M.D.
Executive Vice President, Chief Financial Officer
Executive Vice President, Chief Financial Officer
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Paul Jai Sekhri
Mr. Paul Jai Sekhri
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
5.00K
-24062.00%
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Independent Director
Independent Director
2.15K
+2146.00%
Dr. Raymond Cheong, M.D., Ph.D.
Dr. Raymond Cheong, M.D., Ph.D.
Independent Director
Independent Director
1.83K
+1833.00%
Mr. Richard S. (Rich) Nelson
Mr. Richard S. (Rich) Nelson
Executive Vice President - Corporate Development, Director
Executive Vice President - Corporate Development, Director
--
--
Mr. Fahed Al Marzooqi, M.D.
Mr. Fahed Al Marzooqi, M.D.
Independent Director
Independent Director
--
--
Mr. Burns Mcclellan
Mr. Burns Mcclellan
Investor Relations
Investor Relations
--
--
収益内訳
FY2023
会社から関連データがまだ開示されていません。
地域別USD
会社名
収益
比率
United States
0.00
0.00%
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Fri, Feb 6
更新時刻: Fri, Feb 6
株主統計
種類
株主統計
株主統計
比率
MacAndrews & Forbes Holdings, Inc.
23.18%
Samsara BioCapital, LLC
7.58%
Trails Edge Capital Partners LP
5.87%
Fidelity Management & Research Company LLC
4.90%
Invus Public Equities Advisors, LLC
4.14%
他の
54.33%
株主統計
株主統計
比率
MacAndrews & Forbes Holdings, Inc.
23.18%
Samsara BioCapital, LLC
7.58%
Trails Edge Capital Partners LP
5.87%
Fidelity Management & Research Company LLC
4.90%
Invus Public Equities Advisors, LLC
4.14%
他の
54.33%
種類
株主統計
比率
Holding Company
23.18%
Investment Advisor
17.37%
Venture Capital
7.58%
Hedge Fund
4.34%
Investment Advisor/Hedge Fund
0.75%
Individual Investor
0.42%
他の
46.35%
機関投資家保有株
更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
44
1.18M
30.04%
+255.03K
2025Q3
47
1.15M
29.13%
+562.26K
2025Q2
54
1.51M
57.66%
-17.51K
2025Q1
53
1.53M
60.03%
+1.63K
2024Q4
55
1.51M
61.92%
-7.51K
2024Q3
55
1.49M
61.31%
+181.69K
2024Q2
53
1.29M
53.13%
+308.00
2024Q1
64
1.68M
72.07%
+129.32K
2023Q4
64
1.40M
68.78%
-52.49K
2023Q3
72
1.41M
69.35%
-49.61K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
MacAndrews & Forbes Holdings, Inc.
912.98K
23.18%
--
--
Apr 01, 2025
Samsara BioCapital, LLC
298.50K
7.58%
-75.97K
-20.29%
Dec 08, 2025
Trails Edge Capital Partners LP
231.00K
5.87%
+231.00K
--
Aug 29, 2025
Fidelity Management & Research Company LLC
192.89K
4.9%
+14.69K
+8.24%
Sep 30, 2025
Invus Public Equities Advisors, LLC
163.00K
4.14%
--
--
Sep 30, 2025
Baker Bros. Advisors LP
148.31K
3.77%
+51.00K
+52.41%
Sep 30, 2025
The Vanguard Group, Inc.
46.99K
1.19%
+3.81K
+8.84%
Sep 30, 2025
Geode Capital Management, L.L.C.
15.30K
0.39%
+2.43K
+18.90%
Sep 30, 2025
Northern Trust Investments, Inc.
14.07K
0.36%
-1.22K
-7.95%
Sep 30, 2025
Millennium Management LLC
12.94K
0.33%
-2.11K
-14.01%
Sep 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
iShares Micro-Cap ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
比率0.01%
iShares Core S&P Total U.S. Stock Market ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
Nov 15, 2023
Merger
40→1
Nov 15, 2023
Merger
40→1
Nov 15, 2023
Merger
40→1
Nov 15, 2023
Merger
40→1
日付
配当落ち日
種類
比率
Nov 15, 2023
Merger
40→1
Nov 15, 2023
Merger
40→1
Nov 15, 2023
Merger
40→1
Nov 15, 2023
Merger
40→1
